Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Modulation of B Cell Regulatory Molecules CD22 and CD72 in Myasthenia Gravis and Multiple Sclerosis.
Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria.
Retinal nerve fiber layer thickness in benign multiple sclerosis.
Vitamin D and multiple sclerosis.
Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatment-Past, Present, and Future Aspects.
Intractable hiccup caused by spinal cord lesions in demyelination disease.
Fully automatic detection of deep white matter T1 hypointense lesions in multiple sclerosis.
The two sides of pseudo-bulbar disorder in multiple sclerosis: Comparing one patient's experience with a review of the neurologic literature.
Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity.
18F-FDG PET/CT in Tumefactive Multiple Sclerosis.
Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.
Myelin Basic Protein and a Multiple Sclerosis-related MBP-peptide Bind to Oligonucleotides.
The role of information system in multiple sclerosis management.
Sphingosine-1-phosphate receptors as emerging targets for treatment of pain.
Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Re-expression of N-cadherin in remyelinating lesions of experimental inflammatory demyelination.
Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis.
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis.
[Clinical features of neuromyelitis optica and the distribution of Chinese medical syndrome types: a case report of 63 cases].
The structure and function of the S1P1 receptor.
Postural orthostatic tachycardia syndrome: additional phenotypic feature of neuromyelitis optica spectrum disorder.
Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15.
The helminth Trichuris suis suppresses TLR4-induced inflammatory responses in human macrophages.
Pages
« first
‹ previous
…
296
297
298
299
300
301
302
303
304
…
next ›
last »